ReviewAbdominal radiology (New York)2026
Serous borderline ovarian tumor and low-grade serous ovarian cancer.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection.Cell communication and signaling : CCS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most frequent histological subtype of ovarian cancer, accounting for 95% of ovarian cancer. Radiologists are familiar with the imaging appearances of high-grade serous ovarian cancer (HGSOC) that accounts for about 70% of EOC. Low grade serous ovarian cancer (LGSOC) represents 2-5% of ovarian carcinomas and 5-10% of serous ovarian carcinoma. Historically, it was thought that LGSOC and HGSOC were a continuum. It is now clear that these are two completely separate entities. They have different molecular biology and clinical course. As a result of the low prevalence of LGSOC, there is limited data on its imaging findings. In this paper, we illustrate the pathology, molecular biology and treatment options of LGSOC. We present imaging appearances of LGSOC of primary tumor and metastasis in a cohort of 33 patients with pathologically-proven LGSOC. We also elucidate the differences between LGSOC and HGSOC. Since LGSOC often arise from serous borderline ovarian tumors (SBOT), we describe the imaging appearances of SBOT and highlight the differences between these two entities.
Indexed as
Identifiers
40748460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.